Targeted therapies for renal cell carcinoma: Review of adverse event management strategies

Journal of the National Cancer Institute

Volumn 104, Issue 2, 2012, Pages 93-113

  Eisen, Tim ^a   Sternberg, Cora N ^b   Robert, Caroline ^c   Mulders, Peter ^d   Pyle, Lynda ^e   Zbinden, Stephan ^f   Izzedine, Hassan ^g   Escudier, Bernard ^c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BERN   (Switzerland)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ACNE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTERY DISEASE; ARTERY EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BLEEDING; BRAIN DISEASE; BRAIN HEMORRHAGE; BRONCHITIS; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DATA BASE; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG MONITORING; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; FATIGUE; FLATULENCE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLOSSODYNIA; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOKALEMIA; HYPOTHYROIDISM; INSOMNIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LYMPHOCYTOPENIA; MOUTH PAIN; NAIL DISEASE; NAUSEA; NEUTROPENIA; PANCREAS DISEASE; PERICARDIAL EFFUSION; PHYSICIAN; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QT INTERVAL; RASH; RECTUM HEMORRHAGE; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VIRUS INFECTION; VOMITING; WOUND HEALING; XEROSTOMIA;

ANOREXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CARDIOVASCULAR SYSTEM; DRUG ERUPTIONS; EUROPE; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL TRACT; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PNEUMONIA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; PYRROLES; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WEIGHT LOSS; WOUND HEALING;

EID: 84856159566     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr511     Document Type: Review

References (128)

1. EU SmPC Nexavar. http://www.ema.europa.eu/humandocs/Humans/EPAR/nexavar/ nexavar.htm. Accessed November 8, 2010.
2. EU SmPC Votrient. http://www.ema.europa.eu/humandocs/Humans/EPAR/ votrient/votrient.htm. Accessed November 8, 2010.
3. EU SmPC Sutent. http://www.ema.europa.eu/humandocs/Humans/EPAR/sutent/ sutent.htm. Accessed November 8, 2010.
4. EU SmPC Torisel. http://www.ema.europa.eu/humandocs/Humans/EPAR/torisel/ torisel.htm. Accessed November 8, 2010.
5. EU SmPC Avastin. http://www.ema.europa.eu/humandocs/Humans/EPAR/avastin/ avastin.htm. Accessed November 8, 2010.
6. EU SmPC Afinitor. http://www.ema.europa.eu/humandocs/Humans/EPAR/ afinitor/afinitor.htm. Accessed November 8, 2010.
7. Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009;14(3):291-302.
8. Hutson TE, Bellmunt J, Porta C, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010;46(13):2432-2440.
9. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757-763.
10. Porta C, Szczylik C, Bracarda S, et al. Short-and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26. Abstract 5114.
11. Sternberg CN, Hawkins RE, Szczylik C, et al. A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): updated safety results. J Clin Oncol. 2011;29. Abstract 313.
12. Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2010;28(6):1061-1068.
13. Torino F, Corsello SM, Barnabei A, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6(4):219-228.
14. Bamias A, Lainakis G, Manios E, et al. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol. 2009;27(15):2567-2569.
15. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917-930.
16. Khakoo AY, Plana JC, Champion JC, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-2508.
17. US PI Votrient. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022465s002lbl.pdf. Accessed November 8, 2010.
18. US PI Sutent. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 021938s010s011s014s015lbl.pdf. Accessed November 8, 2010.
19. Grunwald V, Miller K, Machiels J, et al. An international expanded access program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who are intolerant or have progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). Ann Oncol. 2010;21(suppl 8):viii274. Abstract 877PD.
20. Pelz H. Compassionate use-program (CUP) temsirolimus in patients with advanced renal cell carcinoma in Germany. Eur Urol Suppl. 2009;8(4):183. Abstract 251.
21. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115(11):2438-2446.
22. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. (Pubitemid 46849157)
23. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.
24. Albiges L, Caramella C, Dromain C, et al. Interstitail pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis. Eur J Cancer Suppl. 2009;7(2):427. Abstract PD-7114.
25. Pablo M, Hudes G, Dutcher J, et al. Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus. Eur J Cancer Suppl. 2009;7(2):426. Abstract PD-7113.
26. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010;36(5):416-424.
27. Wood LS. Managing the side effects of sorafenib and sunitinib. Commun Oncol. 2006;3(9):558-562. (Pubitemid 44785334)
28. Negrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl. 2007;5(7):12-19. (Pubitemid 350017071)
29. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299-305.
30. Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl. 2008;7(9):593-600.
31. Ivanyi P, Winkler T, Ganser A, et al. Novel therapies in advanced renal cell carcinoma: management of adverse events of sorafenib and sunitinib. Dtsch Arztebl Int. 2008;105(13):232-237. (Pubitemid 351506918)
32. Guenova E. Palmar-plantar erythrodysesthsia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease. Arch Dermatol. 2008;144(8):1081-1082.
33. Wood LS, Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs. 2007;11(5):649-656.
34. Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7(4):127-134.
35. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev. 2009;35(3):297-307.
36. Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557-566.
37. Wood LS. Targeted therapies for advanced renal cell carcinoma: part II-sorafenib. Oncology Nursing News. 2007;(November/December):37-38.
38. Grunwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie. 2007;30(10):519-524. (Pubitemid 47462063)
39. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886-892. (Pubitemid 352039741)
40. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59-e61.
41. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20-23.
42. Hong DS, Reddy SB, Prieto VG. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Arch Dermatol. 2008;144(6):779-782.
43. Kong HH, Cowen EW, Azad N. Keratocanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56(1):171-172.
44. Marquez CB, Smithberger EE, Bair SM. Multiple keratocanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control. 2009;16(1):66-69.
45. Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage. 2008;36(4):413-423.
46. US PI Afinitor. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022334s6lbl.pdf. Accessed November 8, 2010.
47. Bellmunt J. The oncologist's view: targeted therapies in advanced renal cell carcinoma. Eur Urol Suppl. 2008;7(2):55-62.
48. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82(13):1127-1132. (Pubitemid 20213253)
49. Turner JS, Cheung EM, George J, et al. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007;99(5, pt B):1305-1312. (Pubitemid 46624173)
50. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. http://www.nccn.org/. Accessed February 17, 2010.
51. Hands DJ, Eccles B, Geldart TR. An underinvestigated toxicity of sunitinib: red cell macrocytosis. J Clin Oncol. 2011;29(suppl 7). Abstract 371.
52. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559-568.
53. Blowers E, Hall K. Managing adverse events in the use of bevacizumab and chemotherapy. Br J Nurs. 2009;18(6):351-356.
54. Badgwell BD, Camp ER, Fieg B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577-582. (Pubitemid 351325682)
55. Ezzedine S, Bege T, Berdah S, et al. Endoscopic management of colonic perforation owing to angiogenesis inhibitors. Surg Laparosc Endosc Percutan Tech. 2010;20(6):e230-e232.
56. Bamias A, Lainakis G, Manios E, et al. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother. 2009;21(3):347-350.
57. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. New Engl J Med. 2008;358(1):95-97.
58. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9(4):320-328. (Pubitemid 47377031)
59. Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132-143.
60. Ivanyi P, Pencs N, Winkler T, et al. Cardiovascular AE, hypertension and antihypertensive therapy during sunitinib treatment in patients with metastatic renal cell carcinoma (mRCC)-a retrospective analysis of 72 patients. Ann Oncol. 2011;21(suppl 8):viii297. Abstract 946.
61. Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13(10):1084-1096.
62. Chen MH. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep. 2009;11(3):167-174.
63. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2005;23(16S):3554.
64. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):381S-453S. (Pubitemid 351894916)
65. Elice F, Rodeghiero F, Falanga A, et al. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115-128.
66. Thibault F, Billemont B, Richard F, et al. Perioperative use and surgical complications of sunitinib in metastatic renal cell carcinoma. J Urol. 2008;179(4):169.
67. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Resp Crit Care Med. 2010;182(3):396-403.
68. Goodman VL, Wang Q, Pandite LN, et al. Incidence and management of hepatic toxicity in pazopanib-treated patients. Ann Oncol. 2011;21(suppl 8):viii282. Abstract 904P.
69. Xu CF, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54(6):1237-1243.
70. Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102(9):1371-1377.
71. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001-1011.
72. Wood LS, Lemont H, Jatoi A, et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Commun Oncol. 2010;7(1):23-29.
73. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177-182.
74. Hogan CM. The nurse's role in diarrhea management. Oncol Nurs Forum. 1998;25(5):879-886.
75. Tuchmann L, Engleking C. Cancer-related diarrhea. In: Gates RA, Fink RM, eds. Oncology Nursing Secrets. 2nd ed. Philadelphia, PA: Hanley and Belfus; 2001:310-322.
76. Benson AB III, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926. (Pubitemid 41079912)
77. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007;13(4):181-198.
78. O'Brien BE, Kaklamani VG, Benson AB III. The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer. 2005;4(6):375-381. (Pubitemid 41268773)
79. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
80. Escudier B, Ravaud A, Oudard S, et al. Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann Oncol. 2008;19(s8). Abstract 720.
81. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;(4):CD000978. doi:10.1002/14651858. CD000978.pub4.
82. Arcavi L, Shahar A. [Drug related taste disturbances: emphasis on the elderly]. Harefuah. 2003;142(6):446-450.
83. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111. (Pubitemid 350296300)
84. Andrew IM, Waterfield K, Hildreth AJ, et al. Quantifying the impact of standardized assessment and symptom management tools on symptoms associated with cancer-induced anorexia cachexia syndrome. Palliat Med. 2009;23(8):680-688.
85. Berk L, James J, Schwartz A, et al. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008;16(10):1179-1188.
86. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24(21):3401-3407. (Pubitemid 46638896)
87. Lesniak W, Bala M, Jaeschke R, et al. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome-a systematic review and meta-analysis. Pol Arch Med Wewn. 2008;118(11):636-644.
88. Madeddu C, Maccio A, Panzone F, et al. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009;10(8):1359-1366.
89. Mazzotta P, Jeney CM. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated Fatty acids in the management of symptoms, survival, and quality of life. J Pain Symptom Manage. 2009;37(6):1069-1077.
90. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. (Pubitemid 46089672)
91. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
92. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101(10):1717-1723.
93. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81-83.
94. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448-454.
95. Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29(6):807-813.
96. Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104(2):241-247.
97. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19(2):265-268. (Pubitemid 351201706)
98. Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010;28(5):515-519.
99. Flaig TW, Kim FJ, Schoen J, et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009;27(1):83-87.
100. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187. (Pubitemid 46924065)
101. Brenner BM, Cooper ME, de ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
102. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
103. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117-123.
104. Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol. 2007;18(6):1121-1122. (Pubitemid 47050509)
105. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48(4):622-627. (Pubitemid 44843865)
106. Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27(36):6152-6159.
107. Miura S, Fujino M, Matsuo Y, et al. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res. 2005;28(2):147-153. (Pubitemid 40663066)
108. Altena R, de Vries EG, Gietema JA, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391-399.
109. Force T, Kerkelae R. Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem. Drug Discov Today. 2008;13(17-18):778-784.
110. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613-1618.
111. Chen MH, Rupnick MA, Chu TF, et al. Cardiotoxicity associated with sunitinib-Authors' reply. Lancet. 2008;371(9620):1245.
112. Chu TF, Rupnick MA, Kerlela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-2019. (Pubitemid 350236338)
113. Wong MK, Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy. 2009;29(4):473-478.
114. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180(1):94-98.
115. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134. (Pubitemid 46089673)
116. Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum. 2007;34(3):693-701.
117. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843-850. (Pubitemid 32119100)
118. Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010;21(5):1027-1031.
119. Ranze O, Hofmann E, Distelrath A, et al. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie. 2007;30(8-9):450-451. (Pubitemid 350194942)
120. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-1280.
121. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865-4873.
122. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285.
123. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232-1239. (Pubitemid 47299901)
124. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505. (Pubitemid 350232226)
125. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919-4926.
126. Cauley DH, Atkinson BJ, Corn PG, et al. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): a single-center experience. J Clin Oncol. 2011;29(suppl 7). Abstract 332.
127. Bjarnason GA, Khalil B, Williams R, et al. Effect of an individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): correlation with dynamic microbubble ultrasound (DCE-US) data. J Clin Oncol. 2011;29(suppl 7). Abstract 356.
128. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT trial. J Clin Oncol. 2011;29. Abstract LBA308.